Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech - the AI and physics combo.

Ghent is boosting its biopharma hub with cutting-edge infrastructure, world-class research, and a thriving life sciences ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

The companies Cogent Biosciences, Braveheart Bio, and AAVantgarde bagged the biggest biotech funding rounds overall in ...

Igyxos’ IGX12 brings a fresh approach to infertility treatment, aiming to improve outcomes for both men and women.

Delve into Vandria's technology and its Alzheimer's candidate, VNA-318, the first mitophagy-based candidate in Alzheimer's in ...

A new wave of metabolic disease drugs beyond GLP-1 agonists is emerging to address the unmet needs of patients.

In one of the standout deals of the year so far, Roche entered into a $5.3 billion collaboration and license agreement with peptide therapeutics company Zealand Pharma to co-develop and ...

The emergence of dual-payload antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs) could mark a significant evolution in targeted therapeutics. Unlike traditional single-payload designs, ...

In the life science industry, the rise of more complex biologics like bispecific antibodies, fusion proteins and antibody-drug conjugate (ADC) therapies are placing new demands on development ...

For over a hundred years, psychiatry has existed at the intersection of science and art. Unlike other fields of medicine, which rely on blood tests, cultures, imaging, or tissue samples for diagnosis, ...

Since the first biosimilar approval in Europe twenty years ago, biosimilars have provided 6.9 billion patient treatment days and now provide 12% of the total volume of biologic treatments in Europe.